Tarextumab

Tarextumab
Notch 3
Clinical data
Other names	OMP-59R5
ATC code	none;
Legal status
Legal status	Investigational;
Identifiers
CAS Number	1359940-55-8;
ChemSpider	none;
UNII	333YMY788E;
KEGG	D11775;
Chemical and physical data
Formula	C6338H9804N1700O1990S48
Molar mass	143196.94 g·mol−1

Tarextumab (formerly OMP-59R5) is a fully human

3 receptors. It is being tested as a possible treatment for cancer. In January 2015, the US FDA granted orphan drug designation to tarextumab for the treatment of pancreatic cancer and lung cancer.^[1] Two early stage clinical trials have reported encouraging results.^[1]

References

^ ^a ^b "Tarextumab Gets FDA Orphan Drug Designation for Lung, Pancreatic Cancer". 2015.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[FDOD-1] "Tarextumab Gets FDA Orphan Drug Designation for Lung, Pancreatic Cancer". 2015.

[1]

See also

References